After launching two new Rise medical cannabis dispensaries earlier this month, U.S. cannabis company Green Thumb Industries Inc. (CSE: GTII; OTCQX: GTBIF) is now gearing up to open a storefront in Massachusetts.
The new Rise Amherst location will officially open for business this weekend on May 12, 2019 to serve any Massachusetts medical cannabis patients over the age of 20. Like other Rise locations, this site will feature an open retail floor plan and a separate section for patient consultations.
Located in Hampshire County, Amherst is known for its proximity to five separate universities. The company entered the Amherst area back in May of 2018, and has since received accolades from the Amherst Chamber of Commerce for bringing in tax revenue and cannabis awareness.
Regarding the new storefront opening, company founder and Chief Executive Officer Ben Kovler had this to say:
Rise Amherst joins the growing roster of Green Thumb stores, which also saw the addition of Rise Lorain and Rise Toledo last week for the Ohio medical cannabis market.
While recreational usage was legalized in Canada last year with the Cannabis Act, it remains illegal at the federal level in the U.S. Despite that nationwide prohibition, 33 individual states have legalized cannabis for medical purposes, while 10 states have defied the federal government and legalized recreational usage.
Additional recreational legalization attempts are expected to hit the ballot in several states during the upcoming 2020 elections, and a variety of contenders for the Democratic Presidential nomination have openly stated their support for nationwide legalization.
While both large licensed producers and grassroots activists work towards widespread acceptance of cannabis, executives from companies such as Green Thumb have made high-profile appearances at business conferences to make the case for marijuana.
Most recently, CEO Kovler spoke at conferences in Toronto, New York, and California to discuss the legalized industry.
About Author
The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Grizzle hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.